ClinicalTrials.gg

Program

LTP001

A development code.

In Novartis's pipeline, SMURF1 inhibitor. Its studies are mostly in Pulmonary Arterial Hypertension · Idiopathic Pulmonary Fibrosis, led by Novartis.

Furthest: phase 2, since Nov 16, 20213 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis30 open or runningphase 2since Nov 16, 2021Nov 16, 2021none ahead
  • Named in Novartis’s own pipeline as LTP001, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 16, 2021First study: phase 2 study in Pulmonary Arterial HypertensionFirst studyNCT05135000 · 47 enrolled · United States, Argentina, Germany and more
  2. Aug 5, 2022Phase 2 study in Idiopathic Pulmonary FibrosisNCT05497284 · 46 enrolled · United States, Argentina, Australia and more
  3. Jan 10, 2023Phase 2 study in Pulmonary Arterial HypertensionNCT05764265 · 31 enrolled · United States, Argentina, Germany and more

TargetBeta

“SMURF1 inhibitor”the company's pipeline, read by Claude · source

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05764265Pulmonary Arterial Hypertension · United States, Argentina, Germany and more2TerminatedApr 26, 202431
NCT05497284Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more2TerminatedAug 26, 202446
NCT05135000Pulmonary Arterial Hypertension · United States, Argentina, Germany and more2TerminatedMar 20, 202447

How it is read

Names in the registry

  • “LTP001”, 3 entries

Codes read as this program: LTP001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.